Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles(Queen Mary University of London), Elizabeth R. Plimack(Fox Chase Cancer Center), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Tom Waddell(The Christie NHS Foundation Trust), V.P. Stus(Ministry of Health), Rustem Gafanov(Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology), Dmitry Nosov(Central Clinical Hospital and Polyclinic), Frédéric Pouliot(Université Laval), Bohuslav Melichar(Palacký University Olomouc), Ihor Vynnychenko(Sumy State University), Sérgio Jobim Azevedo(Hospital de Clínicas de Porto Alegre), Delphine Borchiellini(Université Côte d'Azur), Raymond S McDermott(University College Dublin), Jens Bedke(University of Tübingen), Satoshi Tamada(Osaka City University Hospital), Lina Yin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mei Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), L. Rhoda Molife(MSD (UK) Limited (United Kingdom)), Michael B. Atkins(Georgetown Lombardi Comprehensive Cancer Center), Brian I. Rini(Cleveland Clinic)
Cited by 738
Abstract
Related Papers
No related papers found
Powered by citation graph analysis